Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

医学 胰腺癌 免疫疗法 肿瘤科 腺癌 癌症 内科学 化疗 进行性疾病 癌症研究
作者
Lijuan Qiu,Chen Liu,Heping Li
出处
期刊:Anti-Cancer Drugs [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/cad.0000000000001546
摘要

Pancreatic cancer is a highly malignant tumor, and most patients are diagnosed at an advanced stage. Unfortunately, due to the immunosuppressive tumor microenvironment of pancreatic cancer, the benefits of immunotherapy for patients with advanced pancreatic cancer are still unclear. Here, we present two cases of advanced pancreatic cancer being controlled by immunotherapy, with pathological diagnoses of ductal adenocarcinoma and acinar cell carcinoma, respectively. Next-generation sequencing (NGS) of both patients is high tumor mutation burden (tumor mutation burden—High) and microsatellite stable. The patient with pancreatic ductal adenocarcinoma was diagnosed as a locally advanced disease (stage III). She received irreversible electroporation, used the programmed death receptor-1 (PD-1) inhibitor (pembrolizumab) combined with chemotherapy (S-1), and then used only the PD-1 inhibitor as a maintenance treatment. As a result, the patient’s lesion was significantly reduced, with a partial response time of up to 31 months. The patient with acinar cell carcinoma was diagnosed as a metastatic disease (stage IV), next-generation sequencing revealed mutations in SMAD4 and KMT2D, and two chemotherapy regimens were used unsuccessfully. Then, the combination of chemotherapy with PD-1 (tislelizumab) and vascular endothelial growth factor/vascular endothelial growth factor receptor (anlotinib) inhibitors were used, and the lesions of the patient were significantly reduced, and the progression-free survival after immunotherapy was 19 months. In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
12345发布了新的文献求助10
1秒前
2秒前
2秒前
2秒前
SY完成签到,获得积分10
5秒前
5秒前
幽默孤容发布了新的文献求助30
7秒前
FashionBoy应助郑一萌采纳,获得10
8秒前
jacob258发布了新的文献求助10
8秒前
酷波er应助x无法显示采纳,获得10
9秒前
9秒前
krkr完成签到,获得积分10
9秒前
9秒前
长干发布了新的文献求助10
10秒前
11秒前
小二郎应助老迟到的寒蕾采纳,获得10
13秒前
zzpj应助截图疯子采纳,获得10
14秒前
Fury发布了新的文献求助10
14秒前
紫金大萝卜应助ggbod采纳,获得20
14秒前
15秒前
FashionBoy应助12345采纳,获得10
16秒前
17秒前
18秒前
糖醋可乐完成签到,获得积分10
19秒前
自然的音响完成签到,获得积分10
23秒前
yessay完成签到,获得积分10
23秒前
HHH发布了新的文献求助10
24秒前
26秒前
林半斤完成签到,获得积分10
26秒前
28秒前
30秒前
失眠亦凝发布了新的文献求助10
34秒前
35秒前
pan应助普通的查查采纳,获得10
36秒前
打打应助Fury采纳,获得10
36秒前
37秒前
在水一方应助aidiresi采纳,获得10
38秒前
ZXJ1009发布了新的文献求助10
39秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
少脉山油柑叶的化学成分研究 430
Revolutions 400
MUL.APIN: An Astronomical Compendium in Cuneiform 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2454727
求助须知:如何正确求助?哪些是违规求助? 2126360
关于积分的说明 5415796
捐赠科研通 1854984
什么是DOI,文献DOI怎么找? 922513
版权声明 562340
科研通“疑难数据库(出版商)”最低求助积分说明 493597